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Although signiﬁcant advances have recently been made in the understanding and treatment of multiple sclerosis, reduction of
long-term disability remains a key goal. Evidence suggests that inﬂammation and oxidative stress within the central nervous
system are major causes of ongoing tissue damage in the disease. Invading inﬂammatory cells, as well as resident central nervous
system cells, release a number of reactive oxygen and nitrogen species which cause demyelination and axonal destruction, the
pathological hallmarks of multiple sclerosis. Reduction in oxidative damage is an important therapeutic strategy to slow or
halt disease processes. Many drugs in clinical practice or currently in trial target this mechanism. Cell-based therapies oﬀer an
alternative source of antioxidant capability. Classically thought of as being important for myelin or cell replacement in multiple
sclerosis, stem cells may, however, have a more important role as providers of supporting factors or direct attenuators of the
disease. In this paper we focus on the antioxidant properties of mesenchymal stem cells and discuss their potential importance as
a cell-based therapy for multiple sclerosis.
1.Introduction
In recent years, clinical trials of stem cell therapiesfor neuro-
logicaldisordershavebegun.Speciﬁcallyinmultiplesclerosis
(MS), a number of trials studying the potential of bone-
marrow-derived stem cell therapies have been published [1–
3]. The initial experimental rationale was to regard stem
cells as multipotential cells capable of diﬀerentiating into
central nervous system cells able to replace lost or damaged
cells in diseased tissue. Indeed, major research programmes
of myelin repair are ongoing [4]. A further, and potentially
more clinically applicable, function of stem cells is their
ability to modulate disease processes. Mesenchymal stem
cells (MSCs) have potent immune modulatory eﬀects in
experimental models [5]. Furthermore, MSCs are able to
secrete a variety of substances that may attenuate disease
processesorprovidetrophicsupportforthediseasednervous
system [6, 7]. In MS, oxidative stress is associated with
signiﬁcant damage to myelin and axons, which in turn leads
to clinical symptoms [8]. A major research strategy for many
years has been to developtherapies which reduce the damage
caused by oxidative stress and thus reduce tissue injury. This
paper will focus on stem cells, and speciﬁcally MSCs, as
providers of antioxidant function for central nervous system
cells.
2.Mechanisms ofTissueDamage inMS and
ExperimentalModelsofCNS Inﬂammation
2.1. The Immunology of Multiple Sclerosis. Multiple sclerosis
has classically been thought of as a T-cell-dependent process
associated with macrophage-mediated demyelination driven
by myelin-speciﬁc autoantigens. Evidencefor the central role
of T cells includes the presence of Th1 (T helper) cytokines,
receptors, and cells in the CSF, circulation, and lesions of
MS patients [9–11]. Furthermore, CD4+ T cells polarized
to Th1 phenotype play a central role in the animal model
of MS, experimental autoimmune encephalomyelitis (EAE)
[12]. In recent years, however, it has become clear that the2 Autoimmune Diseases
immunological interplay in MS is much more complicated
than ﬁrst thought. Evidence countering the central role
for CD4+ T cells includes the fact that MHC class 1-
restricted CD8+ cells are the predominant cell type found in
active MS lesions [13]; lymphocytes may not be present in
early demyelinating lesions and perivascular inﬂammatory
cuﬀs can occur in normal appearing white matter [14]. In
addition, therapies such as anti-interleukin 12p40 that target
CD4+ T-cell function have proved ineﬀective in clinical trials
[15]. These and other developments have led to the need
for further interrogation of the underlying immunology of
the condition and redirected eﬀorts to focus on alternative
cell types that may contribute to the pathogenesis of MS.
Previously, unknown contributors to the disease process
include Th17 cells (producing IL 17), B cells, CD8+ cells,
and both CD4+ and CD8+ T-regulatory cells. Other eﬀector
populations include CD56+ natural killer cells, invariant NK
cells, and stem cells [16]. There is also evidence for the role
of humoral immunity in MS demonstrated by the presence
of immunoglobulin on macrophages actively phagocytosing
myelin [17], immunoglobulin and complement in degener-
ating myelin sheaths [18], and by the occurrence of plasma
cells in plaques [19].
2.2. Patterns of Tissue Injury in MS and Experimental
Demyelinating Models. Pathological changes noted in post-
mortem or (more rarely) biopsy tissue from patients suf-
fering from MS have revealed some of the mechanisms of
tissue damage. Several patterns of tissue injury have been
demonstrated. Although only able to oﬀer a “snap shot” of
tissue damage, certain common themes, some speciﬁcally
relating to oxidative damage, have emerged.
(i) Classical Actively Demyelinating Lesions. There is a
broad spectrum of immunological ﬁndings with
some lesions dominated by T cells and macrophages,
whilst others are notable for their immunoglob-
ulin and complement components. Experimental
demyelinating lesions can be induced by cytotoxic
T cells, autoantibody generation, and genetic abnor-
malities giving further indications of the variety of
factors that may determine an in vivo lesion [20]. In
EAE, inoculation with myelin components, includ-
ing myelin basic protein (MBP), proteolipopro-
tein, myelin oligodendrocyte glycoprotein, myelin-
associated glycoprotein, and S100 protein, elicits an
immunological response mediated via CD4+ MBP-
reactive T cells resulting in paralytic signs in the
host organism. In EAE, demyelinating lesions require
the presence of T cells, myelin autoantibodies, and
complement activation though the relevance of this
observation to MS is not fully established [21].
(ii) Slowly Expanding Lesions of Progressive MS. These
are notable for the presence of a rim of acti-
vated microglia at their periphery with associ-
ated active demyelination. Macrophages containing
myelin degradation products are not found within
these lesions. T-cell inﬁltrates are located perivascu-
larly but are not prevalent [22].
(iii) Cortical Demyelination. Cortical lesions are most
commonly found in the deep sulcal structures in
band-like subpial lesions [23]. Within these lesions,
profound microglial activation can be viewed largely
in the absence of lymphocytes[24]. The presence of a
multitude of inﬂammatory cells within the meninges
overlying these lesions has led some to hypothesise
that they are driven by soluble factors released by the
overlying cells [20].
(iv) Diﬀuse White Matter Injury. The so called “normal
appearing white matter” (NAWM) (deﬁned on mag-
netic resonance imaging)infact demonstratespatho-
logical abnormalities in MS patients, particularly in
the progressive stages of the disease [25]. There is
a predominance of CD8+ MHC class I-restricted
Tl y m p h o c y t e si nad i ﬀuse inﬂammatory inﬁltrate
found particularly in the perivascular space. There
is widespread activation of microglia expressing
footprint activation antigens of radical production,
and microglial activation is closely associated with
diﬀuse axonal injury/loss. There is no doubt that
some Wallerian degeneration of axons occurs fol-
lowing focal demyelinating lesions, but within the
NAWM there is a greater degree of inﬂammation
and microglial activation than would be expected
with Wallerian degeneration alone [20]. Many of
the mechanisms leading to diﬀuse injury in NAWM
are poorly understood; within activated microglia,
frequently found in NAWM, there is expression of
type-II nitric oxide synthases suggesting that oxygen
and nitric oxide radicals are involved in the process;
nitric oxide/oxygen free radicals inhibit enzymes of
the respiratory chain causing mitochondrial dysfunc-
tion [26] which may be an important factor driving
axon dysfunction; the size-dependent axonal loss in
NAWM suggests energy deﬁciency which may also
play an important role in the progressive axon loss
characterising the latter stages of the disease [27].
2.3. Oxidative and Nitrative Stress. Reactive oxygen species
(ROS) and reactive nitrogen species (RNS) are generated
as part of normal cellular physiology. However, if there is
overproduction of ROS or a failure of antioxidant mecha-
nisms, these speciescancause damagetolipids, proteins,and
nucleic acids and may lead to cell death. CNS neurones are
constantly exposed to low levels of these oxidative/nitrative
species which can easily be dealt with by inherent repair
and protection mechanisms. In the inﬂammatory state,
however, these defences can become overwhelmed leading to
oxidative/nitrative stress and damage to the basic structural
and functional elements of the cells. Reactive oxygen and
nitrogen speciesincludesuperoxideions, hydrogenperoxide,
nitric oxide, and peroxynitrite, all of which are produced as
part of the inﬂammatory response and have a potential role
in tissue damage in multiple sclerosis. High levels of NO,
peroxynitrite, and superoxide have all been demonstrated in
spinal ﬂuid from patients with MS [28].Autoimmune Diseases 3
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Figure 1: Cellular detoxiﬁcation of reactive oxygen and nitrative
species. Oxygen is reduced to superoxide (O
−
2 )d u r i n gi n ﬂ a m -
mation, and nitric oxide (NO−) is generated by the action of
inﬂammatory nitric oxide synthase (iNOS) on L-arginine. In the
absence of detoxifying enzymes, NO− and O
−
2 react to produce
the highly toxic peroxynitrite (ONOO−). Superoxide dismutase
(SOD) competes for the superoxide anion and dismutes it to form
hydrogen peroxide (H2O2) which can then be removed by the
enzymes catalaseand glutathione peroxidase (GPX).
There are several reasons why the CNS is particularly
vulnerable to oxidative damage. These include the fact that
brain tissue is very active in oxidative metabolism leading
to relatively high levels of intracellular superoxides: the
limited ability of the CNS to engage in anaerobic respiration
resulting in high levels of superoxides in a hypoxic environ-
ment [29];cellularfeaturespredisposing tooxidativedamage
within the oligodendrocyte population including low levels
of antioxidant defences, membrane elaborations, and high
iron content; the composition of myelin as a preferential
target of ROS due to high protein:lipid ratio [30].
2.3.1. Reactive Nitrogen Species. Nitric oxide (NO) is pro-
duced in the nervous system in response to inﬂammation
through the induction of inﬂammatory nitric oxide synthase
(iNOS). It has been demonstrated that there is increased
iNOS production, and by implication NO species, in the
CNS of animals with EAE, [31]. There is also evidence
of increased proinﬂammatory cytokine production in MS,
and by extension NO [9]. Further indirect evidence of NO
production includes the following: TNFα and IFNγ have
been identiﬁed in astrocytes within both CNS lesions and
CSF white blood cells of patients with MS [32]; higher
levels of NO have been demonstrated within the peripheral
monocytes of patients with MS compared with control
subjects [33]; nitrite and nitrate levels are elevatedin theCSF
of patients with MS [34]. Direct evidence includes the fact
that iNOS mRNA has been identiﬁed in MS plaques [35]
with evidence that macrophages, astrocytes, and microglia
within active lesions express high levels of iNOS and
endothelialNOS[36]. There is also evidencefor thepresence
of reactive nitrogen species in MS through nitrotyrosine, a
m a r k e ro ft h ep r e s e n c eo fp e r o x y n i t r i t e ,w h i c hi sf o u n di n
the diseased brain particularly in areas of demyelination and
inﬂammation [37].
Reactive nitrogen species have a wide variety of eﬀects
on cells through the modiﬁcation of protein structure and
function:theyinhibitseveralenzymes involvedinrespiration
thereby disrupting mitochondrial function and reducing
ATP content as demonstrated in neurons exposed to NO
[32]; NO is known to aﬀect several of the enzymes involved
in oxidative defence including catalase [38]; it has been
hypothesised that oxidation also results in the production
of epitopes which may provoke autoimmune responses [39];
peroxynitrite can lead to cell death through a number of
mechanisms including aﬀecting cell signalling and through
DNA breakdown [40]; NO can also deaminate DNA [41]
and inhibit repair mechanisms [42]. Both reactive nitro-
gen and oxygen species also aﬀect lipid peroxidation and
consequently membrane function/permeability, which has
implications for the function of embedded proteins within
the lipid bilayer [43].
Oligodendrocytes show particular susceptibility to NO
species and can even be lysed by the levels of NO produced
by activated microglial cells. Experiments have shown that
this lysis can be prevented in coculture by the addition of
antagonists of NO production [44].
High levels of phosphorylation within axon neuro-
ﬁlaments protect against proteolysis. Dephosphorylation
renders the axons more susceptible to proteolytic damage
and axonal degeneration [45]. It has been shown that
inﬂammatory agents, such as nitric oxide (NO), reduce
neuroﬁlament phosphorylation levels and thereby facilitate
axon destruction. It is also known that inﬂammation causes
conduction block and has been demonstrated in vivo that
NO/derivatives can block conduction in both central and
peripheral axons and that demyelinated axons are particu-
larly vulnerable to NO-mediated block [46].
2.3.2. Reactive Oxygen Species. Extensive evidence implies
increased ROS production in inﬂammatory demyelinating
diseases. Human microglia are one of the most potent
producers of superoxide [47], and it is known that during
inﬂammatory demyelinating disease cells such as these are
recruited to lesions within the CNS. Neurons also produce
ROS in response to electrical activity following eicosanoid
production driven by calcium cellular inﬂux [48]. Direct
evidence of lipid peroxidation has been demonstrated in
postmortem brain tissue with ﬁndings pointing to a pivotal
role in early plaque evolution [49]. There is also evidence
for increased ROS production in EAE with macrophagesand
microglialcellsexhibitinghighlevelscomparedwith controls
[50] and for higher levels of superoxide throughout aﬀected
brain areas [51]. It has also been noted that peroxynitrite is
formed very early in the course of EAE and correlates with
disease activity [52].
Oligodendrocytesare susceptibleexperimentally to ROS-
mediated damage at levels which do not aﬀect astrocytes
or macrophages [53]. The high levels of iron found in
oligodendrocytes, reacting with hydrogen peroxide and4 Autoimmune Diseases
(a) (b)
Figure 2: Human bone-marrow-derived mesenchymal stem cells in culture (scale bar = 100 microns).
(a) (b)
Figure 3: Nitric oxide promotes axonal injury to cerebellar neurones in vitro. Immunoﬂuorescent images depicting cerebellar axonal
morphology (a) pre- and (b) posttreatment with 0.1mM NO. Green: axonalmarker SMI 312. Blue: DAPI nuclear stain.
leading to the formation of the highly toxic peroxynitrite,
may explain this susceptibility. In addition, low oligoden-
drocyte levels of glutathione, the failure of expression of
Mn-SOD, and low levels of metallothionein, all important
antioxidants, may contribute [54–56]. Hydrogen peroxide is
produced in peroxisomes which are particularly abundant in
oligodendrocytes during the period of active remyelination,
contributing to the failure of long-term repair of myelin
and the axon loss associated with the progressive stages
of the disease. Furthermore, preoligodendrocytes appear to
be signiﬁcantly more sensitive to oxidative stress compared
to mature oligodendroctes [57] providing further barriers
to repair and remyelination. ROS also have direct eﬀects
on the lipid and protein components of myelin, directly
through peroxidation and indirectly through the production
of matrix metalloproteinases which have been shown to
degrade myelin basic protein.
2.3.3. Detoxiﬁcation of Reactive Oxygen and Nitrogen Species.
Cellspossess adiversearray ofdefencemechanisms toreduce
potentially harmful build-up of ROS, speciﬁcally a number
of antioxidant enzymes including superoxide dismutase,
catalase, glutathione peroxidase, and glutathione reductase
(Figure 1). The balance between ROS/RNS and detoxifying
enzymes within inﬂamed tissue may be crucially important
in determining the extent of cellular damage and tissue
injury.
The cause of axonal degeneration in secondary progres-
sive disease is unknown, but recent evidence has suggested
a role for central nervous system peroxisomes in axonal
maintenance [58]. Peroxisomes are cellular organelles which
are involved in a number of anabolic and catabolic reactions
and may have an important role in the detoxiﬁcation of
inﬂammatory compounds such as ROS. Both SOD and
catalase are producedby peroxisomes, and catalase is speciﬁc
to peroxisomes. Inherited abnormalities in peroxisomal
function cause a variety of neurological disorders, including
X-linked adrenoleucodystrophy and adrenomyeloneuropa-
thy,which sharemany clinical,radiological,andneuropatho-
logical features with multiple sclerosis [59]. Furthermore,
defects in peroxisomal function within the central nervousAutoimmune Diseases 5
system have been implicated in experimental models of neu-
roinﬂammatory and neurodegenerative disease [60]. Thus,
peroxisomes may have vital functions in multiple sclerosis
of limiting tissue damage. We have previously shown that
nitric oxide causes signiﬁcant axonal and neuronal damage
in cell culture models (Figure 3)[ 61] and that the addition
of recombinant SOD to cultures protects cerebellar neurons
from nitric-oxide-mediated injury [62, 63].
3.Cell-Based Approaches to Combat Oxidative
Damage inMultipleSclerosis
An u m b e ro fd i ﬀerent cell-based approaches to repair and
protect against tissue damage in MS have been postu-
lated and are the subject of intense research. Examples
include haematopoietic stem cells which have been used
in an immune-reprogramming capacity and neural stem
cells which are predominantly being explored for their
regenerative potential. Meanwhile, mesenchymal stem cells
(MSCs) (Figure 2) have emerged as promising candidates
in the protection of neurones against the oxidative damage
encountered in MS. Here we describe the biology of MSCs
and the antioxidant properties which may have future
relevance to the treatment of the disease.
3.1. Mesenchymal Stem Cells. The potential therapeutic
applications of MSCs for neurological disorders have gen-
erated great interest. To date, human MSC transplantation
has been shown to improve outcome in a variety of animal
models of neurological disease including that of experi-
mental autoimmune encephalomyelitis, stroke, amyotrophic
lateral sclerosis, Krabbe’s disease, and spinal cord injury
[64–77]. Pilot translational studies of MSC therapy have
also commenced in stroke [78], multiple system atrophy
[79], amyotrophic lateral sclerosis [80], metachromatic
leukodystrophy, and Hurlers syndrome [81], as well as
in multiple sclerosis [82]. Administration of MSC is an
attractive therapeutic option in these disorders as MSCs are
easilyisolatedfromvariousanatomicalsources,haveversatile
growth and diﬀerentiation potential, and their immunosup-
pressive properties make it probable that allogeneic as well
as autologous cell therapy could be considered. This is of
importance since in clinicaltherapiesthe use ofan allogeneic
source for cellular therapy is likely to be more convenient
and feasible than an autologous population which would
take weeks to prepare [83]. Despite having a favourable
safety proﬁle in comparison with some other types of stem
cells, there are undoubtedly risks associated with MSC
treatments which should not go unexplored. The use of an
allogenic MSC bank, for example, would carry with it the
risks of chromosomal abnormalities associated with long-
term cell culture and development of therapies will require
the provision of careful and considered safety studies and
protocols.
MSCs were ﬁrst identiﬁed in 1966 in studies by Frieden-
stein et al., who isolated bone-/cartilage-forming progen-
itor cells from rat bone marrow cells with ﬁbroblast-like
morphology [84]. Since this discovery, the most studied
and accessible source of MSCs has been the bone marrow,
although MSCs have been isolated from a number of tissues
including the liver, foetal blood, cord blood, and amniotic
ﬂuid [85–93]. Unlike the haematopoietic stem cells and their
progeny,culturedMSCsexpressanumberofnonspeciﬁcsur-
face markers, none of which, individually or in combination,
have been shown to achieve high levels of MSC isolation
and enrichment [94–98]. Within the bone marrow, MSCs
comprise 0.001–0.1% of the total population of nucleated
cells [85]. MSCs may be considered multi-potent stem cells
that have the ability to diﬀerentiate down both mesenchymal
and nonmesenchymal lineages. Human MSCs contribute
to the regeneration of mesenchymal tissues such as bone,
cartilage, muscle, ligament, tendon, adipose, and stroma
[85] and can also give rise to cells with ectodermal and
endodermal phenotypes [98–104].
Research suggests that transplantation of MSCs has the
p o t e n t i a lt ob ea ne ﬀective treatment for neurodegenerative
disorders through a multitude of diﬀerent mechanisms
including replacement of lost cells by diﬀerentiation into
functional neural tissue, modulation of the immune system
to prevent further neurodegeneration, and provision of
trophic support for the diseased nervous system [105].
Bone-marrow-derived MSCs are able to evade the allogeneic
immune system, as well as suppress immune responses
directed against third-party cells following intravenous
infusion [106–109]. In addition, when infused into the
circulation, MSCs have the capacity to migrate speciﬁcally to
sites ofbraininjury, thustargetingsites forneuralrepair [75–
77]. Although MSCs display a plethora of neuroprotective
and regenerative properties, increasing evidence implies that
themajormechanisticneuroprotectiveroleofbone-marrow-
derived MSCs is their capacity to secrete a diverse range
of potentially neuroprotective factors including antioxidants
[5, 6, 105, 110–112]. With many antioxidant drugs emerging
as potential therapeutic agents for neurodegenerative disor-
ders [113, 114], these ﬁndings emphasise the potential for
bone-marrow-derived MSCs as therapeutic agents for CNS
neurodegenerative disorders, especially disorders in which
oxidative damage is a key aetiological component.
3.2. Antioxidant Properties of Mesenchymal Stem Cells. MSCs
have direct antioxidant activity that is conducive to neuro-
protection both in vivo and in vitro [5, 7]. In vitro studies
have shown that MSC-conditioned media can confer a neu-
roprotective eﬀect against oxidative insult to both primary
cortical and cerebellar neurons, and also neuroblastoma cell
lines [5–7, 63]. Evidence suggests that one method by which
MSCs exert a neuroprotective eﬀect against oxidative stress
is through the modulation of signalling pathways involved in
antioxidant and stress-related processes. Nitric oxide, whilst
performing many physiological roles at low levels, has been
shown to induce apoptosis ina variety ofcultured peripheral
and central neurons and be involved in degeneration during
central nervous system inﬂammation [115, 116]. It has been
established that these eﬀects are mediated through the p38
MAPkinasepathway[61].Secretedproteinfactors,including
neurotrophic factors and cytokines, are thought to have the6 Autoimmune Diseases
ability to inhibit death-inducing pathways and also activate
cell survival pathways [117, 118]. MSCs have been shown to
protect neurons against toxic insults via modulation of both
the PI3kinase/Akt and MAP kinase pathways [7].
Another mechanism by which MSCs can exert a direct
antioxidant eﬀect is through the secretion of antioxidant
molecules. We have recently shown that bone-marrow-
derived MSCs secrete the extracellular antioxidant molecule
superoxide dismutase 3 (SOD3) [7, 63]. The superoxide dis-
mutasefamily member SOD3is the onlyantioxidant enzyme
that scavenges superoxide in the extracellular compartment
[119] and limits the formation of strong neurotoxic oxidants
including both the hydroxyl radical and peroxynitrite in the
extracellular space. It has been demonstrated in a variety
of studies that SOD3 can attenuate tissue damage and
inﬂammation [120–128]; in addition, SOD3 secretion by
human MSCs has been shown to provide direct neuropro-
tection in cerebellar neurons exposed to nitric oxide and
activated microglia [7, 63]. Experiments show that SOD3
secretionbyhumanbone-marrow-derived MSCsisregulated
synergistically by the inﬂammatory cytokines TNFα and
IFNγ [63]. Both TNFα and IFNγ are important mediators of
the immune system and inﬂammatory processes in the CNS
and are therefore present in the diseased brain. In EAE and
other central nervous system inﬂammatory disorders, both
IFNγ andTNFαareupregulatedand are criticallyinvolvedin
theinitiationandampliﬁcationofthelocalimmuneresponse
[129]. These cytokines also enhance the secretion of the
superoxide ions by a variety of immune and nonimmune
cells [130–133]. In summary, SOD3 secretion by MSCs
is a potentially valuable and regulatable therapeutic anti-
inﬂammatory propertythatmay beofrelevanceto treatment
strategies for inﬂammatory disease of the CNS.
Several studies have looked at the eﬀects of transplanted
MSCs on both the clinical course and immunopathology
of EAE. MSC transplantation confers signiﬁcant therapeutic
capacity to modulate autoimmune processes, resulting in
signiﬁcant reductions in demyelination and lesion size
within the CNS and also reductions in the number of
cellular inﬁltrates in the brains of the host organism [68, 69,
134–137]. Inﬂammatory processes within the CNS involve
activated microglia, astrocytes, macrophages, and lympho-
cytes, releasing a plethora of anti- and proinﬂammatory
cytokines [138]. Evidence from both in vitro and in vivo
studies suggests that MSCs have the ability to inhibit
microglial activation and therefore attenuate inﬂammation
[139–142]. It has also been shown that MSCs are capable
of signiﬁcantly decreasing inducible nitric oxide synthase
(iNOS) expression within microglia [140], thus enhancing
their antioxidative eﬀect. Further supporting evidence has
recently shown that MSCs inhibit molecules associated with
neuronal damage and display a variety of antioxidant eﬀects
when administered to EAE mice [5].
4.Conclusions
MSCs possess a diverse range of properties making them
attractive candidates for cell-based therapies. In particular,
antioxidant functions may be utilised as a strategy to reduce
inﬂammation-driven oxidative stress. Cell-based therapies
for MS are currently in development, and the diverse modes
of action of stem cells make them attractive candidates.
Further work to enhance delivery and targeting of cells,
plus optimising and regulating their antioxidant properties,
is required, but stem cell therapies for MS may form an
important part of the therapeutic armoury for the disease in
years to come.
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